Lepu Medical Technology (Beijing) Co., Ltd.

Shenzhen Stock Exchange:300003.SZ

Sector

🏥 Health Care

Industries

🩺 Medical Instruments

🔬 Clinical Trials

💊 Pharmaceuticals

Location

China

Market Cap

USD 3.42 B

Share Price

USD 1.82

Avg Daily Volume

23,052,820

Change (1 day)

2.19%

Change (1 year)

-16.33%

Change (YTD)

17.04%

Lepu Medical Technology (Beijing) Co., Ltd. Enterprise Value to EBITDA (EV/EBITDA) on June 23, 2025: 27.58

Lepu Medical Technology (Beijing) Co., Ltd. Enterprise Value to EBITDA (EV/EBITDA) is 27.58 on June 23, 2025, a 112.66% change year over year. EV/EBITDA ratio compares the enterprise value to the EBITDA; lower suggests more favorable company valuation.

Lepu Medical Technology (Beijing) Co., Ltd. 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 29.64 on June 23, 2025, which is 7.48% above the current Enterprise Value to EBITDA (EV/EBITDA).
Lepu Medical Technology (Beijing) Co., Ltd. 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 7.88 on June 23, 2025, which is -71.42% below the current Enterprise Value to EBITDA (EV/EBITDA).
Lepu Medical Technology (Beijing) Co., Ltd. average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is 13.70.

Daily

From:

To:

Zoom:

Key data

Date	Enterprise Value to EBITDA (EV/EBITDA)	Free Cash Flow Yield	Dividend Yield	Market Capitalization

Shenzhen Stock Exchange: 300003.SZ

Lepu Medical Technology (Beijing) Co., Ltd.

CEO	Ms. Fei Pu
IPO Date	Oct. 30, 2009
Location	China
Headquarters	37 Chaoqian Road
Employees	8,812
Sector	🏥 Health Care
Industries Medical Instruments 🔬 Clinical Trials 💊 Pharmaceuticals

Description

Lepu Medical Technology (Beijing) Co., Ltd. develops, produces, and sells medical devices and equipment. The company offers cardiovascular interventional products, such as coronary stents and balloons, catheters, guide wires, introducer sheaths, tourniquets, inflation devices, and PCI accessories; structural heart diseases products, including occluders, vascular plugs, delivery systems, and mechanical heart valves; cardiac rhythm management products, which include pacemakers, equipment, leads, and electrophysiology; off-pump coronary artery bypass grafting surgical cardiology products; and PTA balloons and guide wires peripheral interventional products. It also provides critical care products, such as vascular access products, needle free connectors, blood samplers, and pressure transducers; floor and suspended type digital subtraction angiography systems; in vitro diagnostic equipment and biomarkers; hemodialysis catheters and hollow fiber dialyzers; and general surgery products, including surgical staplers and endo surgery accessories. In addition, the company offers cardiovascular system drugs, such as antithrombotic, hypolipidemic, antihypertensive, antianginal, and heart failure treatment; ß-lactamase antibiotics and antifungal antimicrobial drugs; central nervous system drugs comprises painkillers and antidepressants; gastric/duodenal ulcer and chronic liver disease treatment drugs; respiratory system drugs; hypoproteinemia drugs; and activating blood circulation drugs. Further, it provides precision medicine, ECG telemonitoring, and cardiovascular disease consulting and management center services; medical S&T incubation and equity investment, and medical financial services; consultation, online pharmacy, and household medical equipment services; smart devices; and specialized hospital services for cardiovascular diseases, as well as involved in the co-construction of Cath lab. The company was founded in 1999 and is headquartered in Beijing, China.